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Abstract
This review deals with the application of a new prefractionation tool, free-ﬂow
electrophoresis (FFE), for proteomic analysis of colorectal cancer (CRC). CRC is a
leading cause of cancer death in the Western world. Early detection is the single most
important factor inﬂuencing outcome of CRC patients. If identiﬁed while the disease
is still localized, CRC is treatable. To improve outcomes for CRC patients there
is a pressing need to identify biomarkers for early detection (diagnostic markers),
prognosis (prognostic indicators), tumour responses (predictive markers) and disease
recurrence (monitoring markers). Despite recent advances in the use of genomic
analysis for risk assessment, in the area of biomarker identiﬁcation genomic methods
alone have yet to produce reliable candidate markers for CRC. For this reason,
attention is being directed towards proteomics as a complementary analytical tool
for biomarker identiﬁcation. Here we describe a proteomics separation tool, which
uses a combination of continuous FFE, a liquid-based isoelectric focusing technique, in
the ﬁrst dimension, followed by rapid reversed-phase HPLC (1–6 min/analysis) in the
second dimension. We have optimized imaging software to present the FFE/RP-HPLC
data in a virtual 2D gel-like format. The advantage of this liquid based fractionation
system over traditional gel-based fractionation systems is the ability to fractionate
large quantity protein samples. Unlike 2D gels, the method is applicable to both
high-Mr proteins and small peptides, which are difﬁcult to separate, and in the case
of peptides, are not retained in standard 2D gels. Copyright  2005 John Wiley &
Sons, Ltd.
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Epidemiology of colorectal cancer (CRC)
CRC is one of the most common cancers diagnosed
each year in Western countries, accounting for
13–14% of all cancer presentations [1,2] and for
10–13% of all cancer deaths [1,2]. The major
impetus for research into markers of CRC is that,
if detected early, when tumours are still localized
[3], the projected 5 year survival rate is ∼90%.
Unfortunately, most colorectal cancers (∼60%)
present at an intermediate stage with a concomitant
decrease in survival rates [2]. The majority of
colorectal cancers (65–85%) are sporadic in nature,
the result of cumulative somatic mutations [4]. Up
to 30% of patients have a family history of bowel
cancer, of which 6% belong to clearly deﬁned
familial genetic syndromes, such as hereditary
non-polyposis colon cancer (HNPCC) and familial
adenomatous polyposis (FAP). Of the sporadic
risk factors, age is the most important, with the
incidence increasing exponentially after age 50 [5].
Colorectal carcinomas arise from adenomas (also
referred to as polyps), hence the ‘adenoma–carci-
noma sequence’, with a lag time of ∼10 years
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[4,6,7], and the removal of these polyps has been
shown to prevent colorectal cancer [7].
Current detection methods for CRC
In the USA, UK and Australia, the general rec-
ommended screening regimen involves annual to
biennial faecal occult blood tests (FOBT) and 5-
yearly sigmoidoscopies [8,9]. However, effective
population screening by these means is precluded
by patient compliance, due to discomfort and lack
of awareness of the epidemiology of colorectal can-
cer. If used alone, FOBT has been shown to be
ineffective [10]. This type of screening is not diag-
nostic of CRC, but merely selects those patients
who should proceed to colonoscopy.
The most widely used blood-based protein bio-
marker of CRC, carcinoembryonic antigen (CEA),
exhibits poor sensitivity for screening for the early
detection of the disease and is mainly employed in
post-operative detection for recurrence and moni-
toring of metastasis [11,12]. Whilst a single marker
may lack sensitivity and speciﬁcity for detec-
tion, combining markers improves these parameters
[13,14].
Proteomics tools
Current proteomics research can be deﬁned as
two contrasting but complementary strategies, cell-
mapping proteomics and protein expression pro-
teomics [15,16].
Cell-mapping proteomics
Cell-mapping proteomics aims to deﬁne pro-
tein–protein interactions to build a picture of the
complex networks that constitute intracellular sig-
nalling pathways. Many genetic mutations associ-
ated with cancer progression affect genes encod-
ing proteins in signalling pathways, highlighting
the importance of deﬁning these signalling net-
works [17]. For example, Pandey et al. treated
HeLa cells with either epidermal growth factor or
platelet-derived growth factor (PDGF), and used
anti-phosphotyrosine immunoprecipitation to con-
centrate a range of proteins that were subsequently
phosphorylated [18]. The analysis revealed the role
of vav-2, as well as a number of other proteins,
in growth factor signalling. Alternatively, Lewis
et al. selectively activated or inhibited the mitogen-
activated protein kinase (MAPK) pathway and used
a proteomic approach to identify 20 novel targets of
MAPK signalling [19]. Afﬁnity capture techniques
have also been used to identify the anti-apoptotic
protein DIABLO/SMAC [20] and binding proteins
for suppressors of cytokine signalling, SOCS [21].
Although the scope of this review does not cover
the full range of possibilities available, these few
examples show the utility of cell-mapping pro-
teomics.
Protein-expression proteomics
Protein expression analysis monitors global expres-
sion of large numbers of proteins within a cell type
or tissue and quantitatively identiﬁes how patterns
of expression change in different circumstances.
Global protein proﬁles can be produced for normal
compared with tumour cells in a given tissue, or
for cells before and after treatment with a speciﬁc
drug. Currently, this is the most widely used model
of proteomics and is largely dependent upon two-
dimensional gel electrophoresis (2DE) for visual-
ization of protein proﬁles. Expression proteomics
is the protein equivalent of DNA microarray anal-
ysis. Like DNA microarrays, it has the advantage of
being non-prejudicial and could deﬁne unexpected
ways in which known proteins regulate cellular
responses. Major limitations of the 2DE system
include an inability to detect proteins of medium
to low abundance, as well as a limited appar-
ent molecular mass range (Mr), where molecules
smaller than 10 K are generally lost. This has
prompted much interest in non-2DE approaches for
studying global protein proﬁles.
Correlation of mRNA transcripts and
protein expression levels
In the search for tumour progression markers or
anticancer drug targets, there has been a concerted
effort to deﬁne gene expression proﬁles at the tran-
script level [22,23]. However, it is clear that mRNA
expression data alone are insufﬁcient to predict
functional outcomes for the cell, as they provide
very little information about activation state, post-
translational modiﬁcation or localization of corre-
sponding proteins. Moreover, there are numerous
Copyright  2005 John Wiley & Sons, Ltd. Comp Funct Genom 2005; 6: 236–243.238 R. L. Moritz et al.
reports highlighting the disparity between mRNA
transcript and protein expression levels [24,25].
Thus, at the very least, mRNA expression stud-
ies must be supported with proteomic information
in an integrated approach to provide a complete
picture of how cells are altered during malignant
transformation [25,26].
Dynamic range of protein abundances
Several technical issues need to be addressed
before proteomics can realize its full potential for
protein expression proﬁling of complex proteomes
such as cells and tissues [27,28]. Foremost is the
problem of dynamic range of protein abundances.
For instance, the dynamic range of protein abun-
dances in blood is thought to be ∼1010 [29]. This
makes it extremely challenging to visualize low-
abundance proteins and peptides in complex pro-
teomes such as blood, let alone identify them using
current mass spectrometry (MS)-based identiﬁca-
tion methods [30–32]. For example, the most abun-
dant protein in human plasma is serum albumin
(HSA), present at 40–50 mg/ml, whereas some of
the least abundant proteins, such as cytokines [33]
and protease biomarkers (e.g. the prostate-speciﬁc
antigen [34]), are present at ∼10 and ∼3 pg/ml
levels, respectively. Given that the current sen-
sitivity of routine protein and peptide identiﬁca-
tion by MS–MS is ∼500 amol, in order to obtain
500 amol of IL-6, approximately ∼1.5m lp l a s m a
would be required for the initial fractionation step.
However, this amount of plasma would also contain
1.4 µM (90 mg) HSA, which is 6.2 × 109 (w/w)
in excess of IL-6. This is a formidable quantity
of protein to fractionate and presents a challenge
to current puriﬁcation schemes, where extensive
pre-fractionatation/depletion strategies need to be
invoked in order to reveal low-abundance pro-
teins. However, this also assumes that the pro-
tein of interest is homogenous and a 100% recov-
ery is obtained through all fractionation steps.
For IL-6, which is extensively post-translationally
modiﬁed (pI range 5–7, Mr range 22–29 K
[33,35,36]), much larger quantities of plasma
would be required to obtain a single enriched popu-
lation of IL-6 molecules for identiﬁcation purposes.
Of equal importance is the problem that proteins
exhibit tremendous heterogeneity with respect to
size, charge, post-translational modiﬁcations and
solubility. Consequently, a wide range of protein
separation methods, or combinations thereof, i.e.
multidimensional separation strategies, are usually
required for the comprehensive analysis of complex
proteomes.
For several decades, 2DE [37,38] has been the
only proteomics technique that has permitted the
separation of thousands of proteins in a single
experiment [39,40]. However, the dynamic range of
protein abundances that can be separated by 2DE is




Several approaches for overcoming the protein
dynamic range obstacle have been recently descri-
bed, viz. (a) the disassembly of the macromolec-
ular architecture of cells into their constituent
organelles, macromolecular structures and multi-
protein complexes allowing subproteome analysis
[41,42]; (b) enrichment of cellular components
using differential detergent fractionation [43,44] or
molecular weight fractionation [45]; (c) depletion
of abundant proteins using non-biospeciﬁc chro-
matography [46], immunoafﬁnity chromatography
using speciﬁc antibodies against abundant proteins
[47], and removal of IgG from serum using
immobilized protein-A or — G columns [48–52];
(d) selective precipitation, e.g. with triﬂuoracetic
acid/acetone [53] prior to 2DE; and (e) various
chromatographic [54,55] and electrophoretic meth-
ods [56].
Prefractionation of proteins from large volumes,
as a prelude to subsequent analysis using 2DE,
can be performed by preparative polyacrylamide
gel electrophoresis (PAGE) or size-exclusion chro-
matography on the basis of Mr [57,58]. Alterna-
tive electrophoretic prefractionation methods based
upon solution-phase IEF, rather than gel-based IEF
[59] used in 2DE, have been developed. These
non-gel-based IEF methods can accommodate large
sample volumes and amounts in contrast to gel-
based IEF methods. Preparative IEF as a prefrac-
tionation technique was ﬁrst proposed by Bier’s
laboratory [60,61]. To overcome problems asso-
ciated with the original device, Righetti and col-
leagues [62] developed a multicompartment elec-
trolyser in which each compartment was separated
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Figure 1. Schematic representation of the continuous FFE apparatus coupled off-line to RP-HPLC. Dimensions of focusing
chamber: 50 × 10 × 0.04 cm (10 cm between electrodes, 45 cm electrode length). For analytical imaging separations, a
portion of each ﬁrst-dimension FFE-IEF fraction (50 µl/total volume ∼2 ml) was injected directly from the 96 deep-well
plate using the Agilent 1100 HPLC equipped with a well-plate autosampler and samples collected automatically into a
multi-plate fraction collection system
by a polyacrylamide gel membrane, each with a
deﬁned pH. A microscale liquid-phase IEF pre-
fractionation method that is also based upon a
multicompartment apparatus (4.7 ml total volume,
650 µl/chamber) has recently been described by
Speicher et al. [63]. In this apparatus the chambers
are separated by thin polyacrylamide gels contain-
ing ampholyte mixtures at speciﬁc pH values. For a
recent review of prefractionation techniques in pro-
teome analysis, see Righetti et al. [64] and Simpson
[28].
Free-ﬂow electophoresis (FFE)
FFE, ﬁrst described by Hannig, [65,66], is a sep-
aration device that continuously streams a sam-
ple into a carrier ampholine solution ﬂowing as a
thin laminar ﬁlm (0.3–1.0 mm) between two ﬂat
plates (see Figure 1). By introducing an electric
ﬁeld perpendicular to the direction of ﬂow, cellu-
lar organelles, proteins and low Mr species such
as peptides can be separated by IEF according
to their different pI values and subsequently col-
lected for further analysis [67,68]. Previously, we
reported an uncoupled FFE-IEF/SDS-PAGE strat-
egy for separating cytosolic proteins from a human
colon carcinoma cell line for subsequent identiﬁ-
cation by on-line RP-HPLC/electrospray-ionization
(ESI)-ion trap MS [69]. We have further reﬁned
this strategy to provide a complete liquid-based
fractionation strategy by introducing off-line rapid
RP-HPLC (1–6 min separation times) as a sec-
ond dimension for each of the FFE fractions. An
example of a complex protein separation, such as a
cell lysate, using this method is shown in Figure 2.
Unlike 2DE, this technique is suitable for separat-
ing low-Mr proteins and polypeptides and does not
have the problem of sample loadability, due to the
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Figure 2. Two-dimensional FFE-IEF/RP-HPLC separation of cytosolic proteins from untreated and non-steriod
anti-inﬂammatory drug (NSAID)-treated human LIM 1215 colorectal cell line. (A) Sample: 1 mg untreated LIM 1215
cytosolic proteins dissolved in 1 ml IEF running buffer containing 0.2% (w/v) HPMC, 0.4% (v/v) Servalyte pH 3–10 loaded
at 1.4 ml/h at 1500 V, 15 mA and collected into a deep 96-well plate. Second dimension RP-HPLC separation of FFE-IEF
fraction. (B) Sample: 1 mg NSAID-treated LIM1215 cytosolic proteins. FFE-IEF and second dimension RP-HPLC separation
are as in (A); proteins indicated by arrows were dysregulated by NSAID treatment of LIM 1215 cells (R.L. Moritz,
manuscript in preparation)
ease by which the method can accommodate large
sample volumes [70]. FFE can be performed over
both broad and narrow ranges of pH by the judi-
cious choice of ampholytes in the ﬁrst dimension
step. Additionally, we have developed software to
present the chromatographic output as a single 2D
plot (virtual 2D analysis) for quick visual evalua-
tion and ‘spot’ matching of fractionated proteins.
The ability to fractionate low-Mr compounds
is an important feature of this 2D liquid-based
FFE-IEF/RP-HPLC method, because techniques
designed for this purpose are under represented
in the armory of current proteomic separation
tools. 2D gel-based systems, multicompartment and
column-based separation systems are also limited
by the quantity of bulk starting material that can be
loaded in the ﬁrst dimension (IPG). This limitation
in fractionation of starting material can hamper
efforts to mine complex tissues.
The advantages of this system can be summa-
rized as follows: (a) protein and/or peptide separa-
tions in the ﬁrst dimension (IEF) are performed in
a liquid phase and, unlike other multicompartment
electroanalysers, are not restricted by passaging
through any barrier or matrix; (b) the system is
truly preparative by not being sample-limited, and
separation efﬁciency is maintained by continual
ﬂushing of the separated sample; and (c) the FFE-
IEF/RP-HPLC system is capable of separating
compounds of low Mr (e.g. peptides) as well as
high Mr (e.g. native proteins and their multimeric
complexes) over a broad pH range. For those pro-
teins (especially membrane proteins) that exhibit
poor solubility at or near their pI value, an appro-
priate buffer (e.g. amino acids as well as detergents
in the case of membrane protein separations) can
be incorporated in the FFE counterﬂow media prior
to collection in the 96-well plate to minimize the
time that such proteins stand at their pI value
[69]. The high-resolving power produced in the
ﬁrst dimension IEF step, where very narrow range
pH gradients can easily be generated, coupled to
the high resolution of modern RP-HPLC station-
ary phases, extends the resolving power of this
2D protein separation system over other previously
described 2D systems based solely on coupled
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HPLC columns [71,72]. In the case of high-Mr pro-
teins and very hydrophobic proteins such as mem-
brane proteins, the RP-HPLC stationary phases can
be substituted by other chromatographic modes,
such as hydrophobic interaction chromatography
or hydroxyapatite stationary phases to extend the
power of the method to cover classes of proteins
that are refractory to RP chromatography.
The advantage of the 2D liquid-based FFE/RP-
HPLC system over traditional gel-based systems is
that complex mixtures of low-Mr compounds, such
as tryptic peptides, can be fractionated, whereby
peptides are fractionated into discrete pools with
increasing pH values that vary one from another by
∼0.02 pH units. The ease and rapid determination
of the apparent peptide pI value can be achieved
by measuring the pH of these pools using a lab-
oratory combination pH electrode. By applying a
peptide’s pI determinant to high mass accuracy
(1 ppm) peptide-mass ﬁngerprinting, [73–75] the
discrimination of peptides differing by small mass
units or even isobaric peptides is feasible [76].
Peptide mass, as determined by current high mass
accuracy mass spectrometers, by itself as the only
parameter for peptide identiﬁcation in large genome
databases, is insufﬁcient for high-conﬁdence pro-
tein identiﬁcation and is no longer considered a
valid approach to protein identiﬁcation by the edi-
tors of proteomics journals [77]. The use of a pep-
tide’s pI value combined with MS–MS data also
provides a powerful qualiﬁer for peptide identiﬁca-
tions, as well as decreasing the peptide search pool.
The latter can be achieved by minimizing the num-
ber of peptides used to search with, by only con-
sidering those peptides that are within a discrete pI
range in conjunction with the mass range deﬁned
by the accuracy of the mass spectrometer used.
Concluding remarks
The 2D liquid based FFE-IEF/RP-HPLC method
described here promises to play a key role in
the analysis of complex protein and low-Mr com-
pounds, the latter being largely under repre-
sented in most proteome studies to date. Interest-
ingly, low-Mr proteins and peptides are thought
to contain a rich source of previously undiscov-
ered biomarkers of disease [78]. Although current
claims regarding the potential of proteomics to
deﬁne cancer-related molecules might outnumber
reports of concrete achievement, both global-
expression [79,80] and cell-mapping proteomics
[19–21] have contributed to our understanding of
cell biology and disease. To date, several proteins
have been identiﬁed from colon tumour samples
and patient blood that can potentially be used for
biomarkers for the identiﬁcation of early onset col-
orectal cancer [81,82]. Validation of these identi-
ﬁcations must be performed before these proteins
can be ascribed as diagnostic biomarkers [83]. It
is anticipated that further proteomics studies aimed
at identifying speciﬁc proteins present in biological
specimens of diseased patients may reveal a panel
of proteins that correlate with aberrant growth spe-
ciﬁc or individual cancer subtypes. When used in
combination, such a cohort of biomarkers may pro-
vide for a high-sensitivity and -speciﬁcity predic-
tive assay with minimal invasion to the patient,
thereby allowing for population-based screening.
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